IL6 and breast cancer: In particular, the IL-6/STAT3 pathway was found to be preferentially active in CD44+CD24− breast cancer cells, which have stem-cell-like characteristics, compared with other tumor cell types, and the inhibition of JAK2 decreased their number and blocked the growth of xenografts [31].